Johns Hopkins University School of Medicine

How population, community health goals overlapA new study found that distinguishing between population health and community health strategies can help health organizations define clear goals and earmark the right resources to accomplish them.
Novel glaucoma treatments factor in scleral behaviorInnovations in sustained-drug delivery and neuroprotection are bringing glaucoma specialists one step closer to additional therapeutic options.
Neuroprotective drug may be possible NAION therapyNon-arteritic ischemic optic neuropathy can be difficult to treat. A new drug under investigation aims to prevent further loss of vision from the condition.
Tracking treatment adherence in newly diagnosed open-angle glaucoma
Tracking treatment adherence in newly diagnosed open-angle glaucomaAn analysis of U.S. claims data reveals a substantial proportion of patients (17%) remained untreated 4 years after their initial diagnosis of open-angle glaucoma.
Exploring ocular demodicosis in chronic blepharitisBy knowing the signs and symptoms of Demodex, ophthalmologists can better diagnose and offer treatments for blepharitis.
When old, new technologies converge for dry eye diagnosisPhysicians should take a multipronged approach to dry eye disease, especially in its diagnosis, advises David B. Glasser, MD.
‘Super formula’ maximizes accuracy for IOL powersAn IOL “super formula” may broaden the conceptual understanding of IOL calculations, improve clinical outcomes for patients, and stimulate further progress in IOL formula research.
Artificial cornea may be alternative to repeat PK in certain patientsFindings of a retrospective case review show that eyes that underwent implantation of the Boston Type 1 keratoprosthesis had greater improvement in visual acuity than those undergoing repeat donor corneal transplantation.
Novel modalities expand glaucoma therapeutic arsenalActive research in neuroprotection, neuroregeneration, and sustained drug delivery is expected to lead to better options for management of glaucoma.
Nanotechnology suitable match for treatment of eye diseaseCollaborations with practicing ophthalmologists have been crucial to nanotechnology discoveries pertaining to eye diseases, and in which drug can be delivered to the eye.